AbbVie Inc.
www.abbvie.com
Latest From AbbVie Inc.
SELECTION Positive For Gilead/Galapagos’s Filotinib In UC But Will It Be Enough To Compete?
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
Building A Bridge To A COVID-19 Vaccine: Hydroxychloroquine And BCG Lead Prevention Pipeline
More than 40 Phase III trials are assessing pre- and post-exposure prophylaxis of SARS-CoV-2 infection.
New Drug Launches Worldwide Dipped In 2019
The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.
EU Approves Takeda’s Injectable Entyvio for IBD
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
- AbbVie Inc.
- Senior Management
-
Richard A Gonzalez, Chmn. & CEO
Robert A Michael, EVP, CFO
Michael E Servino, MD, Pres.
Carlos Alban, Chief Commercial Officer - Contact Info
-
AbbVie Inc.
Phone: (847) 937-6100
1 N. Waukegan Rd.
North Chicago, IL 60064
USA